Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 7Acromegaly 4Prostatic Neoplasms 3Carcinoid Tumor 3Pituitary ACTH Hypersecretion 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Thyroid Neoplasms 1Serotonin Syndrome 1Prolactinoma 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Nelson Syndrome 1Myelodysplastic Syndromes 1Meningioma 1Melanoma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1

Interventions

lutetium Lu 177 dotatate 2pembrolizumab 1pasireotide 1lanreotide 1folfirinox 1copper dotatate CU-64 1arginyllysine 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytokines 1Cryotherapy 1Carboplatin 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastro-enteropancreatic neuroendocrine tumor × pasireotide × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡